about
Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trialsEvaluation of 8q24 and 17q risk loci and prostate cancer mortality.Evaluation of the 8q24 prostate cancer risk locus and MYC expression.Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer.A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors.Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.Smoking and alcohol use may be risk factors for poorer outcome in patients with clear cell renal carcinoma.Use of androgen deprivation therapy for metastatic prostate cancer in older men.Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population.Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer.Treatment of bicalutamide-induced gynecomastia with breast-reduction surgery in prostate cancer.Development of an integrated prostate cancer research information system.Relationship between serum adiponectin and prostate cancer grade.Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer.Secondary hormonal therapies in the treatment of prostate cancer.Does oral antiandrogen use before leuteinizing hormone-releasing hormone therapy in patients with metastatic prostate cancer prevent clinical consequences of a testosterone flare?Complementary and alternative therapies in prostate cancer.SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancerNeoadjuvant therapy before radical prostatectomy in high-risk localized prostate cancer: defining appropriate endpoints.Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular cancer: a long-term update.Genome-wide association study of prostate cancer mortalityThe evolving role of chemotherapy and other systemic therapies for managing localized prostate cancer.Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research.PC3 is a cell line characteristic of prostatic small cell carcinoma.Recent progress in hormonal therapy for advanced prostate cancer.Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy.Trends in the use of cytoreductive nephrectomy in the United States.The medical management of prostate cancer: a multidisciplinary team approach.Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer?The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid.Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer.Functional enhancers at the gene-poor 8q24 cancer-linked locus.Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review.Sixty years of CA: a cancer journal for clinicians.Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.Overcoming castration resistance in prostate cancer.Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successes.The emerging role of circulating tumor cell detection in genitourinary cancer.Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysis.
P50
Q24599547-ADB3F01B-92FA-4593-A13E-FF710DD62B56Q30494721-845EEB96-B61A-4866-AA3A-BA3EDC38B2D0Q30494853-8CEA27E1-E70B-467C-97DB-4B6E0910A7D9Q33231043-DDA17C13-B9A6-4530-81EC-9FC5EC35041AQ33358093-12FCB70A-AF25-4B3D-93DE-5DD11FC30096Q33396609-B9A54C95-D0AD-4213-A0B5-EFBC5ADD7773Q33510317-0D671555-DA02-408D-8299-888BAE4E584EQ33828156-5173E7A9-926E-4453-B9B3-C37EBA9F6B87Q33977514-B40A9DB1-4F37-48FB-B3C5-7FD43A8DA521Q34268286-7E2BC90B-8D62-4E68-9C78-405C3AEF54C2Q34338135-7BF70BC9-2561-4DC5-90BE-B5BD095895AAQ34539610-0FD0665F-5AED-4015-96BA-6C36CAC94739Q34549980-8FDF89E2-9B08-431B-A0E8-A1436CB76543Q34798992-DFA0C075-DDD4-4F1C-90B6-435CFF29EEFEQ34856489-2197904F-97DF-4D04-AAC3-844F0A94214FQ34856725-20D6668A-86BC-4179-B815-0B96C3B76423Q35016110-3A55DC84-7192-4039-BAD4-12424F99A81DQ35040040-5C12F8F6-D21B-4024-B3C1-E89D9DCD6A12Q35112055-8AFD24D4-E960-4EC1-AE63-D3D2697905FBQ35156057-FF4421C4-D8AE-495F-B092-4308CB989307Q35189753-1423536F-786C-486B-ABD6-CAEA59DB8E52Q35399770-725554E8-A971-43D4-8EFA-AC9E2D26BB03Q35580983-7E305C14-38B4-49FF-BB72-974839ABF8EFQ36087881-39D57D2F-E249-4AAD-A518-9A92E7E49DC5Q36185201-5E4AE941-FFD5-4793-B1AB-2AB35F476005Q36470716-67D06D52-7000-4DA8-8E0F-C94641069B16Q36510749-D61FC3F7-44AD-480E-BBCC-296371D4E1B2Q36553501-CE5166FD-487D-4EDE-8D48-C4B2F7B68E4EQ36586934-A2FE55D5-ADD8-4C89-A4D3-5E291056E0C5Q36691329-A1A52DAC-79B5-45F3-9331-CE1AD4DAF336Q36740442-F682E839-D9ED-46DB-91EF-214ADF866A39Q36965080-D9E7E78B-84AE-418F-84ED-71AA2DC9AC03Q37279616-64F171B6-3F57-4728-95DA-4C566B5CB540Q37623007-DC88A5CA-24DC-4841-A97E-A7D4B82509B6Q37809409-0B9C60DB-8E56-4F96-9C6C-92FE685F8EE5Q37873687-020F1218-345C-48C5-8625-570B53CA839CQ37999597-B16AD278-A0BE-441D-A5EA-93B10183CB84Q38005622-CDA9828A-FAA5-4ABE-A1C9-94357D311122Q38009457-14564A11-50F9-4B35-90EA-49D59EE884C2Q38014986-F1E5E4BA-6A80-45A4-BC1A-3E9D9AAADE34
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
William K Oh
@nl
William K Oh
@sl
William K. Oh
@en
William K. Oh
@es
type
label
William K Oh
@nl
William K Oh
@sl
William K. Oh
@en
William K. Oh
@es
prefLabel
William K Oh
@nl
William K Oh
@sl
William K. Oh
@en
William K. Oh
@es
P1053
B-9163-2012
P106
P21
P31
P3829
P496
0000-0001-5113-8147